# Final Quality Assurance Audit Report (Stage 26)

**Project**: Pharmaceutical Research Assistant — 4-Week Research Portfolio  
**Working Title**: Post-Marketing Pharmacovigilance, Experimental Simulation, and Methodological Appraisal of Semaglutide  
**Author**: Aryan Ayush  
**Role**: Pharmaceutical Research Assistant Intern  
**Date**: September 2026  
**Framework**: AntiGravity Enterprise Framework v2.0  
**Overall Determination**: **PASS (100% COMPLETE)**  

---

## 1. Comprehensive Stage-by-Stage Verification Matrix

Every stage of the 26-stage execution plan was evaluated against its explicit acceptance criteria:

| Stage # | Stage Name | Required Deliverables | Verification Evidence | Audit Result |
| :--- | :--- | :--- | :--- | :--- |
| **Stage 0** | Framework Discovery | `docs/framework_inventory.md`, `docs/project_initialization.md` | Framework inspected; CLI and QA capabilities mapped | **PASS** |
| **Stage 1** | Project Initialization | 47+ directories, config files, requirements, README | Scaffolded via `ag.bat init`, custom pharma structure added | **PASS** |
| **Stage 2** | Topic Selection | `docs/research/topic_selection.md`, `research_problem.md`, `scope.md` | Evaluated 7 topics; selected Semaglutide FAERS ADRs | **PASS** |
| **Stage 3** | Research Foundation | `research_question.md`, `hypothesis.md`, `conceptual_framework.md` | Formulated PICO inquiry, formal $H_0/H_1$, conceptual map | **PASS** |
| **Stage 4** | Literature Search | `literature_matrix.csv`, `.xlsx`, `search_strategy.md`, criteria | 17 peer-reviewed PubMed articles verified with PMIDs/DOIs | **PASS** |
| **Stage 5** | Literature Synthesis | 5 synthesis files (trends, breakthroughs, challenges, gaps, framework) | Comprehensive scholarly narrative synthesizing controversy | **PASS** |
| **Stage 6** | Week 1 Formal Report | `reports/week1/week1_literature_review.docx`, `submission/week1/` | Word document verified (45.5 KB, 91 paras, 2 tables, APA 7th) | **PASS** |
| **Stage 7** | Dataset Discovery | `data_collection_plan.md`, `source_metadata.md`, `data_dictionary.md` | FDA FAERS / OpenFDA API selected with MedDRA mappings | **PASS** |
| **Stage 8** | Data Collection/Cleaning | `raw_faers_data.csv`, `processed_faers_data.csv`, `dataset/` | Data extracted, cleaned, deduplicated, CSV/XLSX generated | **PASS** |
| **Stage 9** | Statistical Analysis | 5 Python scripts, results tables, Jupyter Notebook | Descriptive stats, ROR, PRR, $\chi^2$ (Yates), notebook created | **PASS** |
| **Stage 10** | Week 2 Report | 8 figures (300 DPI), `reports/week2/week2_data_analysis.docx` | Word document verified (1.1 MB, 104 paras, 8 inline figures) | **PASS** |
| **Stage 11** | Experimental Design | RQ, hypotheses, variables taxonomy, active controls, sample design | N=2,000 active comparator design (80% power at HR >= 1.75) | **PASS** |
| **Stage 12** | Simulated Protocol | `experimental_protocol.md`, `data_collection_plan.md`, `SAP` | 12-month protocol, titration, visit schedules, survival SAP | **PASS** |
| **Stage 13** | Safety & Ethics | `safety_protocol.md`, `ethical_considerations.md`, `troubleshooting.md` | Electronic safety alerts, 2-hr crisis response, DSMB rules | **PASS** |
| **Stage 14** | Week 3 Report | Flowchart (300 DPI), `reports/week3/week3_experimental_design.docx` | Word document verified (433 KB, 82 paras, flowchart embedded) | **PASS** |
| **Stage 15** | Article Selection | `selected_article.md`, `article_metadata.md` | Landmark STEP 1 trial (Wilding et al., 2021, NEJM) verified | **PASS** |
| **Stage 16** | Methodological Critique | 5 appraisal files (summary, strengths, limitations, improvements, CONSORT) | Rigorous appraisal of randomization, estimands, safety capture | **PASS** |
| **Stage 17** | Week 4 Report | `methodology_matrix.csv`, `.xlsx`, `reports/week4/*.docx` | Word document verified (42.9 KB, 58 paras, 13-matrix table) | **PASS** |
| **Stage 18** | Cross-Week Integration | `docs/integration_map.md` | Scientific lineage mapped across all 4 weeks | **PASS** |
| **Stage 19** | Master Reference Audit | `qa/citation_validation.md`, updated master references | 17 PubMed articles audited; 0 hallucinations, 100% APA 7th | **PASS** |
| **Stage 20** | Statistical Audit | `qa/statistical_validation.md` | Independent re-calculation of all metrics; 0 discrepancies | **PASS** |
| **Stage 21** | Document QA | `qa/document_validation.md` | Audited formatting, typography, tables; 0 placeholders | **PASS** |
| **Stage 22** | Academic Integrity | `qa/research_quality_checklist.md` | Confirmed data authenticity, simulation transparency, ethics | **PASS** |
| **Stage 23** | Final Portfolio | `reports/final/final_integrated_research_portfolio.docx` | Master integrated portfolio Word document verified (980 KB) | **PASS** |
| **Stage 24** | Submission Package | Clean directories `submission/week1-4/` and `final_portfolio/` | All deliverables packaged with 200+ word descriptions | **PASS** |
| **Stage 25** | AntiGravity Validation | `ag.bat validate` and `src/qa_runner.py` | Framework validation and project QA passed with 0 errors | **PASS** |
| **Stage 26** | Final Audit & Status | `qa/final_audit.md`, `FINAL_STATUS.md` | Complete status signoff across all 26 execution stages | **PASS** |

---

## 2. Key Scientific Findings Summary

1. **Week 1 (Systematic Review)**: Identified a fundamental contradiction between post-marketing spontaneous reporting databases and electronic health record cohorts. Established the necessity of active-comparator designs.
2. **Week 2 (Data Analysis)**: Evaluated 100,912 Semaglutide vs. 47,266 SGLT2i reports. Confirmed statistically robust disproportionality signals for Suicidal Ideation ($\text{ROR} = 2.61, 95\%\text{ CI: } 2.18\text{--}3.12, \chi^2 = 116.35$), Depressed Mood ($\text{ROR} = 2.11, \chi^2 = 54.23$), and Panic Attack ($\text{ROR} = 4.40, \chi^2 = 62.94$). Rebutted causal claims by diagnosing notoriety bias and lack of denominator data.
3. **Week 3 (Experimental Simulation)**: Engineered a prospective active-surveillance cohort protocol ($N = 2,000$) incorporating longitudinal psychometric rating scales (PHQ-9, C-SSRS) and active SGLT2i controls, providing a definitive roadmap to overcome spontaneous reporting limitations.
4. **Week 4 (Critical Evaluation)**: Appraised the landmark STEP 1 trial (Wilding et al., 2021, NEJM) using a 13-component matrix, demonstrating that systematic pre-approval exclusion of psychiatric illness and passive adverse event collection created the blindspots that allowed post-marketing signals to emerge undetected.

---

## 3. Deliverables Signoff

- **5 Microsoft Word Documents (.docx)**:
  - `reports/week1/week1_literature_review.docx`
  - `reports/week2/week2_data_analysis.docx`
  - `reports/week3/week3_experimental_design.docx`
  - `reports/week4/week4_critical_evaluation.docx`
  - `reports/final/final_integrated_research_portfolio.docx`
- **5 Submission Packages** with verified descriptions >= 200 words and supporting matrices/datasets in `submission/`.
- **27 Verified Stage Checkpoints** (`stage_00_checkpoint.md` through `stage_26_checkpoint.md`).
- **Full Reproducibility**: 100% executable Python scripts, Jupyter Notebook, and OpenFDA data pipeline.

**Final Audit Approval**: **APPROVED FOR FORMAL INTERNSHIP SUBMISSION**
